Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
The inspection was concluded with zero observations
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Subscribe To Our Newsletter & Stay Updated
